Konturek Peter C
ChA/Klinik für Innere Med. II/Saalfeld, Thüringen-Kliniken "Georgius Agricola" GmbH, Rainweg 68, 7318, Saalfeld, Deutschland.
MMW Fortschr Med. 2022 Jul;164(Suppl 7):12-15. doi: 10.1007/s15006-022-1230-3.
Intestinal dysbiosis remains the focus of research into the pathogenesis of chronic inflammatory bowel disease (IBD). The potential role of gut microbiota in the development of IBD includes interaction with the host genome and immune system, as well as various environmental factors, diet, drugs, industrialization, etc. Other organs are negatively affected by intestinal dysbiosis via gut-brain axis. The composition of microbiota and its metabolic activity has a significant impact on the effectiveness of anti-inflammatory therapies. Microbiome-based treatment for IBD includes the use of diet, antibiotics, pre-, pro- and synbiotics, and faecal transplantation (FMT). The development of effective therapies for IBD patients will only be possible once the interactions between the microbiota and its metabolites and the host immune system are better understood.
肠道菌群失调仍然是慢性炎症性肠病（IBD）发病机制研究的重点。肠道微生物群在IBD发生发展中的潜在作用包括与宿主基因组和免疫系统以及各种环境因素、饮食、药物、工业化等相互作用。其他器官会通过肠-脑轴受到肠道菌群失调的负面影响。微生物群的组成及其代谢活性对抗炎治疗的效果有重大影响。基于微生物群的IBD治疗方法包括饮食、抗生素、益生元、益生菌和合生元的使用以及粪便移植（FMT）。只有更好地理解微生物群及其代谢产物与宿主免疫系统之间的相互作用，才有可能为IBD患者开发出有效的治疗方法。
